GlassScriptPhysician profile
Daniel J Urschel
NPI 1174752661
$1,133.15
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $73.01 · 2021: $77.83 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $700.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $75.80 | 2019-2020 | |
| Kaleo, INC. | $72.31 | 2019-2021 | |
| Sobi, INC | $40.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.65 | 2020 | |
| Biocryst US Sales Co., LLC | $25.70 | 2021 | |
| Tris Pharma INC | $23.62 | 2019 | |
| Chiesi USA, INC. | $18.63 | 2021 | |
| Grifols USA, LLC | $12.19 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Urschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.